ECM
KRYS icon

Evergreen Capital Management’s Krystal Biotech KRYS Stock Holding History

Evergreen Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Buy
1,124
+30
+3% +$8.96K 0.01% 1012
2026
Q1 		$283K Buy
1,094
+8
+0.7% +$2.13K 0.01% 1163
2025
Q4 		$268K Buy
+1,086
New +$229K 0.01% 1113
2025
Q2 		– Sell
-1,348
Closed -$243K – 1198
2025
Q1 		$243K Buy
+1,348
New +$227K 0.01% 875

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Evergreen Capital Management's KRYS Position: Q2 2026 in Review

Evergreen Capital Management increased its Krystal Biotech (KRYS) stake by 2.7% in Q2 2026, buying an estimated $8.96K and bringing the position to 1,124 shares worth $418K. The position accounts for 0.01% of the portfolio, ranked #1012.

Evergreen Capital Management first reported a position in KRYS in Q1 2025 and has held it in 4 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Evergreen Capital Management held 1,124 shares of Krystal Biotech worth $418K as of Q2 2026.
  • Evergreen Capital Management bought 30 Krystal Biotech shares in Q2 2026, an estimated $8.96K.
  • Krystal Biotech made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #1012 holding.
  • Evergreen Capital Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 4 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.